We are live on ! Find out more

Aclaris Therapeutics

ACRS

Market cap $587M

3.99 USD

+0.03

0.76%

At close Updated Oct 29, 4:00 PM EDT

Pre-market

After hours

3.99

0.00

0%

1 day

0.76%

5 days

4.72%

1 month

-24.43%

3 months

-22.07%

6 months

-10.74%

Year to date

38.54%

1 year

70.51%

5 years

-77%

10 years

-81.22%

About: Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.

Employees: 73

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 18.2%

Neutral 63.6%

Negative 18.2%

Aclaris Therapeutics ATI-052 Posts Early Eczema, Asthma Signals in Phase 1b

Aclaris Therapeutics NASDAQ: ACRS reported Phase 1b proof-of-concept results for ATI-052, its bispecific antibody designed to inhibit thymic stromal lymphopoietin (TSLP) and IL-4 receptor alpha, in small studies of atopic dermatitis and asthma. The company said the treatment was well tolerated and produced early clinical and biomarker signals in both indications.

Aclaris Therapeutics ATI-052 Posts Early Eczema, Asthma Signals in Phase 1b

Aclaris Therapeutics, Inc. (ACRS) Discusses ATI-052 Proof-of-Concept Results in Atopic Dermatitis and Asthma Transcript

Aclaris Therapeutics, Inc. (ACRS) Discusses ATI-052 Proof-of-Concept Results in Atopic Dermatitis and Asthma Transcript

Aclaris Therapeutics, Inc. (ACRS) Discusses ATI-052 Proof-of-Concept Results in Atopic Dermatitis and Asthma Transcript

Aclaris Therapeutics Announces Pricing of $50.0 Million Offering of Common Stock and Pre-Funded Warrants

WAYNE, Pa., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced the pricing of an underwritten offering of 7,785,714 shares of its common stock at a price of $3.50 per share and, in lieu of shares of common stock to certain investors, pre-funded warrants to purchase 6,500,000 shares of common stock at a purchase price of $3.49999 per share, which equals the offering price per share of the common stock less the $0.00001 exercise price per share of each pre-funded warrant. All of the shares of common stock and the pre-funded warrants are to be sold by Aclaris.

Aclaris Therapeutics Announces Pricing of $50.0 Million Offering of Common Stock and Pre-Funded Warrants

Aclaris Therapeutics Announces Positive Phase 1b Proof-of-Concept Primary Analysis Results for its Anti-TSLP/IL-4Rα Bispecific ATI-052 in Atopic Dermatitis (AD) and Asthma

Aclaris Therapeutics Announces Positive Phase 1b Proof-of-Concept Primary Analysis Results for its Anti-TSLP/IL-4Rα Bispecific ATI-052 in Atopic Dermatitis

Aclaris Therapeutics Announces Positive Phase 1b Proof-of-Concept Primary Analysis Results for its Anti-TSLP/IL-4Rα Bispecific ATI-052 in Atopic Dermatitis (AD) and Asthma

Zacks Investment Research

Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?

Here is how Aclaris Therapeutics (ACRS) and Glaukos (GKOS) have performed compared to their sector so far this year.

Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?

Zacks Investment Research

Aclaris (ACRS) Soars 6.0%: Is Further Upside Left in the Stock?

Aclaris (ACRS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Aclaris (ACRS) Soars 6.0%: Is Further Upside Left in the Stock?

Aclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

WAYNE, Pa., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that on Thursday, September 10, 2026, at 2:45 PM ET, Aclaris' Chief Executive Officer Dr. Neal Walker will participate in a fireside chat during the 2026 Cantor Global Healthcare Conference in New York, NY.

Aclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

Zacks Investment Research

Wall Street Analysts Believe Aclaris (ACRS) Could Rally 69.2%: Here's is How to Trade

The consensus price target hints at a 69.2% upside potential for Aclaris (ACRS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Believe Aclaris (ACRS) Could Rally 69.2%: Here's is How to Trade

Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP)

WAYNE, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the U.S. Food and Drug Administration (the "FDA") has granted Fast Track Designation for modzatinib (ATI-2138) for moderate to severe lichen planus (LP) including oral erosive LP, cutaneous LP, and lichen planopilaris. Aclaris expects to initiate a phased multi-part Phase 2b trial of modzatinib in LP in the fourth quarter of 2026.

Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP)

Zacks Investment Research

Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates

Aclaris Therapeutics (ACRS) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to a loss of $0.13 per share a year ago.

Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates

See News Rankings

Price charts implemented using Lightweight Charts™